WO2015130660A1 - Synthesis of racemic amphetamine derivatives by cuprate addition reaction with aziridine phosphoramidate compounds - Google Patents

Synthesis of racemic amphetamine derivatives by cuprate addition reaction with aziridine phosphoramidate compounds Download PDF

Info

Publication number
WO2015130660A1
WO2015130660A1 PCT/US2015/017265 US2015017265W WO2015130660A1 WO 2015130660 A1 WO2015130660 A1 WO 2015130660A1 US 2015017265 W US2015017265 W US 2015017265W WO 2015130660 A1 WO2015130660 A1 WO 2015130660A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
process according
aryl
alkyl
Prior art date
Application number
PCT/US2015/017265
Other languages
French (fr)
Inventor
Harold Meckler
Brian Thomas Gregg
Jie Yang
Original Assignee
Chemapotheca, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/189,630 external-priority patent/US9278904B2/en
Priority claimed from US14/327,209 external-priority patent/US9321794B2/en
Application filed by Chemapotheca, Llc filed Critical Chemapotheca, Llc
Publication of WO2015130660A1 publication Critical patent/WO2015130660A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/62—Preparation of compounds containing amino groups bound to a carbon skeleton by cleaving carbon-to-nitrogen, sulfur-to-nitrogen, or phosphorus-to-nitrogen bonds, e.g. hydrolysis of amides, N-dealkylation of amines or quaternary ammonium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2475—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aralkylamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/564—Three-membered rings

Definitions

  • This is invention is related to processes for synthesis of amphetamine derivatives and novel intermediates thereby.
  • amphetamine derivatives have led to the development of numerous synthetic methods for their synthesis and their derivatization.
  • One problem with amphetamine synthesis is that amphetamines have a stereo-defined amine center, which can be difficult to resolve and subject to racemization. Accordingly, for the preparation of a single stereoisomer, only stereospecific methods are useful. However, stereospecific methods do not provide the economic requirements of high yields, high selectivity and low process costs.
  • the stereo center is purchased as part of a chiral starting material or utilize tedious and expensive synthetic reactions to achieve that goal.
  • Such reactions involve a coupling agent, such as Grignard or organolithium reagents.
  • a coupling agent such as Grignard or organolithium reagents.
  • Conventional teaching requires that the use such organometallics requires that the reaction temperature be maintained at a cold temperature, such as an ice bath at less than 10 degrees Celsius.
  • racemic amphetamine To complicate the amphetamine marketplace, there are established formulations which require racemic amphetamine to obtain an extended release of elevated blood levels of the drug.
  • This racemic material can be obtained by mixing equal parts of the dextrorotary and levorotary stereos isomers or running a synthetic sequence which only produces racemic amphetamine.
  • the present invention addresses one or more of the shortcomings of the prior art by providing processes for the synthesis of amphetamine, dexamphetamine, methamphetamine, derivatives of these, including their salts, and novel precursors and intermediates obtained thereby, by synthesizing aziridine phosphoramidate compounds in specified solvents at specified temperatures, and then converting to a novel aryl or aryl-alkyl phosphoramidate precursors using a modified organometallic compound such as a organocopper reagent, where the novel aryl or aryl-alkyl phosphoramidate precursor is then easily converted to the target compounds using known reactions, e.g. acidification, alkylation of the nitrogen followed by dephosphorylation, etc.
  • a modified organometallic compound such as a organocopper reagent
  • the invention provides a synthetic pathway to amphetamine derivatives using an aziridine based process with an organometallic compound by heating the reactants in a first step, and then adding as a second step the Grignard reagent in a dosage controlled fashion.
  • the reaction is heated to above 40 degrees C, preferably above about 45 degrees C, and more preferably above about 48 degrees C.
  • the temperature is maintained from 48-51 deg. C for about 30 minutes and then brought to room temperature.
  • the invention provides a process of making the amphetamine, said process comprising:
  • R is alkyl or aryl
  • the amphetamine process comprises wherein the acidic conditions are aqueous hydrochloric, sulfuric or phosphoric acids.
  • the amphetamine process comprises wherein the aqueous acid water content is in an amount of 50% to 90%
  • the amphetamine process comprises wherein said providing a compound of Formula 6 comprises:
  • R is alkyl or aryl
  • the amphetamine process comprises wherein the
  • regioisomeric purity of Formula 6 is > 99% and the regioisomer (Formula 8) is ⁇ 0.1%.
  • the amphetamine process comprises wherein the copper catalyst is CuCl, CuCl 2 , CuBr, CuF, Cul, Cu(OAc) 2 , Cu(OMe)2, Copper nanoparticles, Copper turnings, or combinations thereof.
  • the amphetamine process comprises wherein the solvent is an organic ether or an organic ether-toluene mixture.
  • the amphetamine process comprises wherein the organic ether solvent is diethyl ether, tetrahydrofuran or 2-methyltetrahydrofuran.
  • the amphetamine process comprises wherein the
  • phenylmagnesium halide is either phenylmagnesium chloride, phenylmagnesium bromide or phenylmagnesium iodide.
  • the amphetamine process comprises wherein the
  • phenylmagnesium halide solutions can either be commercially supplied or prepared in situ from the corresponding halobenzene and magnesium.
  • the amphetamine process comprises wherein the magnesium is be in the form of chips, granules, ribbon, turnings, dust, grit, blocks or chunks.
  • the amphetamine process comprises wherein said treating is carried out at a temperature of from about -10 °C to about 70 °C.
  • the amphetamine process comprises wherein said providing a compound of Formula 2 comprises:
  • R is alkyl or aryl
  • the amphetamine process comprises wherein the base is potassium hydroxide or potassium carbonate.
  • R is alkyl or aryl
  • the amphetamine process comprises wherein said providing a compound of Formula 4 comprises:
  • R alkyl or aryl
  • R is alkyl or aryl
  • stereoselective or stereoselectivity means without limitation, by way of explanation, the property of a chemical reaction in which a single reactant forms an unequal mixture of stereoisomers during the non-stereospecific creation of a new stereocenter or during the non-stereospecific transformation of a pre-existing one.
  • the selectivity arises from differences in steric effects and electronic effects in the mechanistic pathways leading to the different products.
  • Zwierzak et al. teach in Tetrahedron 1997, 53, 4935-4946 that the product from the organocuprate addition to the 2-alkyl-N-(diethylphosphoryl)aziridines is always regiospecific, always occurring with nucleophilic attack at the less substituted carbon atom of the aziridine ring.
  • Zwierzak continues the paragraph by explaining that diethyl N-sec-alkylphosphoramidate products could be easily isolated in pure state after quenching the organocuprate reaction mixture with aqueous ammonium chloride solution and no further purification is necessary before deprotection. It was discovered in attempting to implement the Zwierzak procedure, that this is not the case.
  • 6a readily crystallizes from hexane, heptane, isooctane or petroleum ether, but the residual 8a is still present It is required to leave a residue of the reaction solvent (THF) in the solvent mixture to separate the 6a from 8a.
  • THF reaction solvent
  • the other versions of 6 (b,c or d) needed other recrystallization solvent mixtures, but the common item was that it was required to leave a residue of THF in the mixture.
  • NMR spectra Proton nuclear magnetic resonance spectra were obtained on a Bruker
  • dimethyl (2methylaziridin-l- yl)phosphonate (2c) is prepared as a viscous colorless oil in about 70% yield (expected 95% GC minimum purity).
  • diisopropyl (2methylaziridin- l-yl)phosphonate (2d) is prepared as a viscous colorless oil in about 50 % yield (expected 95% GC minimum purity).
  • the reaction was quenched by slow addition to a cooled mixture of saturated aqueous ammonium chloride solution and water (50/50 v/v, 100 mL) while maintaining an internal temperature below 20 °C.
  • the flask was rinsed with methyl t- butyl ether (100 mL) and the rinse was transferred to the quenched reaction mixture.
  • the biphasic mixture was stirred for 5 minutes, allowed to separate for 20 minutes and then the aqueous phase was removed.
  • the organic phase washed with saturated sodium chloride solution (50 mL) and the organic phase was dried over sodium sulfate.
  • the solution (a 97:7 mixture of 6a: 8a by GC analysis) was filtered and concentrated under reduced pressure until the product began to crystallize.
  • the reaction was quenched by slow addition to a cooled mixture of saturated aqueous ammonium chloride solution and water (50/50 v/v, 4.2 L) while maintaining an internal temperature below 25 °C.
  • the flask was rinsed with heptanes (3.5 L) and the rinse was transferred to the quenched reaction mixture.
  • the biphasic mixture was stirred for 5 minutes, allowed to separate for 20 minutes and then the aqueous phase was removed.
  • the organic phase was concentrated under reduced pressure to a volume of about 1.0 L.
  • the organic solution was azeotropically dried by two separate charges of heptanes (2 X 2.0L) was added and the solution volume was adjusted by reduced pressure distillation to a total volume of about 2.5 L.
  • halobenzene and magnesium metal turnings For phenylmagnesium chloride, the solvents of choice are either THF or 2-methylTHF. For phenylmagnesium bromide, the solvents of choice are either THF, 2-methylTHF or diethyl ether. For phenylmagnesium iodide the solvent of choice is diethyl ether.
  • THF trifluoride
  • 2-methylTHF 2-methylTHF
  • diethyl ether diethyl ether.
  • reaction mixture was cooled to ambient temperature.
  • the reaction was quenched by slow addition to a cooled solution of saturated aqueous ammonium chloride/water mixture (50/50 v/v, 60 mL) while maintaining the batch temperature below 20 °C.
  • Heptanes 60 mL was used to rinse the reactor and was transferred to the quench mixture.
  • the biphasic mixture was agitated for 15 minutes and the aqueous layer was removed.
  • the organic layer washed with deionized water (20 mL) and the organic phase concentrated under reduced pressure to give viscous oil. This residue was dissolved in heptanes (50 mL) and the solution was concentrated under reduced pressure.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention includes processes for the synthesis of amphetamine, dexamphetamine, methamphetamine, derivatives of these, including their salts, and novel precursors and intermediates obtained thereby, by synthesizing aziridine phosphoramidate compounds in specified solvents at specified temperatures, and then converting to a novel aryl or aryl-alkyl phosphoramidate precursors using an organometallic compound such as a copper salt, where the novel aryl or aryl-alkyl phosphoramidate precursor is then easily converted to the target compounds using known reactions.

Description

APPLICATION FOR GRANT OF LETTERS PATENT
TITLE
Synthesis of Racemic Amphetamine Derivatives by Cuprate Addition Reaction with Aziridine Phosphoramidate Compounds
INVENTORS
MECKLER, Harold, Delmar, NY (US)
GREGG, Brian Thomas, Altamont, NY (US)
YANG, Jie, Rensselaer, NY (US)
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of U.S. Application 14/189,630 filed Feb. 25, 2014, the content of which is incorporated herein in its entirety.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
No federal government funds were used in the research or development of this invention.
NAMES OF PARTIES TO A JOINT RESEARCH AGREEMENT
None.
REFERENCE TO A SEQUENCE LISTING
None.
BACKGROUND
[0001 ] Field of the Invention
[0002] This is invention is related to processes for synthesis of amphetamine derivatives and novel intermediates thereby.
[0003] Background of the Invention
[0004] The commercial importance of amphetamine derivatives has led to the development of numerous synthetic methods for their synthesis and their derivatization. One problem with amphetamine synthesis is that amphetamines have a stereo-defined amine center, which can be difficult to resolve and subject to racemization. Accordingly, for the preparation of a single stereoisomer, only stereospecific methods are useful. However, stereospecific methods do not provide the economic requirements of high yields, high selectivity and low process costs.
Typically, the stereo center is purchased as part of a chiral starting material or utilize tedious and expensive synthetic reactions to achieve that goal. Such reactions involve a coupling agent, such as Grignard or organolithium reagents. Conventional teaching requires that the use such organometallics requires that the reaction temperature be maintained at a cold temperature, such as an ice bath at less than 10 degrees Celsius.
[0005] To complicate the amphetamine marketplace, there are established formulations which require racemic amphetamine to obtain an extended release of elevated blood levels of the drug. This racemic material can be obtained by mixing equal parts of the dextrorotary and levorotary stereos isomers or running a synthetic sequence which only produces racemic amphetamine.
[0006] Another problem with amphetamine synthesis is that the intermediates are toxic as well as flammable. This requires special handling such as double-walled drums and safety accommodations to protect manufacturing personnel.
[0007] The prior art in U.S. Pat. 6,399,828 teaches the production of amphetamine using various methods. In one approach norephedrine is refluxed with hydrogen iodide and red phosphorous. In another approach norephedrine is chlorinated using thionyl chloride and then catalytically hydrogenated. In U.S. Pat. 7,705,184, amphetamine synthesis is disclosed using hydrogenation of a chlorinated phenylpropanolamine. Aziridine chemistry, and specifically aziridine phosphoramidates are not taught in the amphetamine synthesis prior art.
[0008] Zwierzak et al. disclose a method of reacting N-phosphorylated aziridines with copper-modified Grignard reagents as a new route to substituted pyrrolines and pyrrolidines. However, Zwierzak et al discloses this method as being regiospecific, which it is not. Synthetic Communications: An Int'l J. for Rapid Commun. of Syn. Org. Chem., 28:7, 1127-1137 (1998).
[0009] Additionally, the use of protecting groups and leaving groups is well known.
However, it has been discovered that there is significant variation among the various standard protecting groups. Specifically, where a carbonyl moiety is used as the amine protecting group (i.e. acetyl t-Boc or CBZ), the reaction must be kept at or below -10 degrees Celsius or the carbonyl will react with the organometallic reagent. Where a sulfonyl moiety is used as an amine protecting group (i.e. methanesulfonyl or p-toluenesulfonyl), it is difficult to remove the protecting group without destroying the molecule.
[00010] Accordingly, there is a need for synthetic processes and useful compounds for the manufacture of amphetamine and its derivatives that have high chemical yield, high selectivity, low cost, lower toxicity and are less dangerous to handle.
BRIEF SUMMARY OF THE INVENTION
[00011] The present invention addresses one or more of the shortcomings of the prior art by providing processes for the synthesis of amphetamine, dexamphetamine, methamphetamine, derivatives of these, including their salts, and novel precursors and intermediates obtained thereby, by synthesizing aziridine phosphoramidate compounds in specified solvents at specified temperatures, and then converting to a novel aryl or aryl-alkyl phosphoramidate precursors using a modified organometallic compound such as a organocopper reagent, where the novel aryl or aryl-alkyl phosphoramidate precursor is then easily converted to the target compounds using known reactions, e.g. acidification, alkylation of the nitrogen followed by dephosphorylation, etc.
[00012] In one preferred aspect the invention provides a synthetic pathway to amphetamine derivatives using an aziridine based process with an organometallic compound by heating the reactants in a first step, and then adding as a second step the Grignard reagent in a dosage controlled fashion. In a preferred embodiment, the reaction is heated to above 40 degrees C, preferably above about 45 degrees C, and more preferably above about 48 degrees C. In one embodiment, the temperature is maintained from 48-51 deg. C for about 30 minutes and then brought to room temperature.
[00013] In another preferred embodiment, the invention provides a process of making the amphetamine, said process comprising:
[00014] roviding a compound of Formula 6:
Figure imgf000004_0001
[00016] [00017] wherein R is alkyl or aryl; and
[00018] deprotecting the compound of Formula 6 under acidic conditions effective to produce amphetamine of Formula 7:
Figure imgf000005_0001
[00019] 7
[00020]
[00021] In preferred aspects, the amphetamine process comprises wherein the acidic conditions are aqueous hydrochloric, sulfuric or phosphoric acids.
[00022] In preferred aspects, the amphetamine process comprises wherein the aqueous acid water content is in an amount of 50% to 90%
[00023] In preferred aspects, the amphetamine process comprises wherein the R= methyl, ethyl, isopropyl or phenyl.
[00024] In preferred aspects, the amphetamine process comprises wherein said providing a compound of Formula 6 comprises:
[00025] providing a compound of Formula 2:
P(0)(OR)2
N
H3C
[00026] 2 ;
[00027] wherein R is alkyl or aryl and
[00028] reacting the compound of Formula 2 with phenylmagnesium halide and a copper catalyst under solvent and temperature conditions effective to produce a compound of Formula 6 in a purity substantially free of any regioisomeric impurities.
[00029] In preferred aspects, the amphetamine process comprises wherein the
regioisomeric purity of Formula 6 is > 99% and the regioisomer (Formula 8) is < 0.1%.
[00030] In preferred aspects, the amphetamine process comprises wherein the R= methyl, ethyl, isopropyl or phenyl. [00031] In preferred aspects, the amphetamine process comprises wherein the copper catalyst is CuCl, CuCl2, CuBr, CuF, Cul, Cu(OAc)2, Cu(OMe)2, Copper nanoparticles, Copper turnings, or combinations thereof.
[00032] In preferred aspects, the amphetamine process comprises wherein the solvent is an organic ether or an organic ether-toluene mixture.
[00033] In preferred aspects, the amphetamine process comprises wherein the organic ether solvent is diethyl ether, tetrahydrofuran or 2-methyltetrahydrofuran.
[00034] In preferred aspects, the amphetamine process comprises wherein the
phenylmagnesium halide is either phenylmagnesium chloride, phenylmagnesium bromide or phenylmagnesium iodide.
[00035] In preferred aspects, the amphetamine process comprises wherein the
phenylmagnesium halide solutions can either be commercially supplied or prepared in situ from the corresponding halobenzene and magnesium.
[00036] In preferred aspects, the amphetamine process comprises wherein the magnesium is be in the form of chips, granules, ribbon, turnings, dust, grit, blocks or chunks.
[00037] In preferred aspects, the amphetamine process comprises wherein said treating is carried out at a temperature of from about -10 °C to about 70 °C.
[00038] In preferred aspects, the amphetamine process comprises wherein said treating is carried out at a temperature of from about 30 °C to about 60 °C.
[00039] In preferred aspects, the amphetamine process comprises wherein said providing a compound of Formula 2 comprises:
[00040] roviding a compound of Formula 5:
Figure imgf000006_0001
[00041] 5 ;
[00042] wherein R is alkyl or aryl; and
[00043] reacting the compound of Formula 5 with the base under conditions effective to produce a compound of Formula 2. [00044] In preferred aspects, the amphetamine process comprises a compound of Formula 5 wherein the R= methyl, ethyl, isopropyl or phenyl.
[00045] In preferred aspects, the amphetamine process comprises wherein the base is potassium hydroxide or potassium carbonate.
[00046] In preferred aspects, the amphetamine process comprises wherein said providing a compound of Formula 5 comprises:
[00047] roviding a compound of Formula 4:
Figure imgf000007_0001
[00048] wherein R is alkyl or aryl; and
[00049] reacting the compound of Formula 4 with methanesulfonyl chloride and a base under conditions effective to produce a compound of Formula 5.
[00050] In preferred aspects, the amphetamine process comprises a compound of Formula 4 wherein the R= methyl, ethyl, isopropyl or phenyl.
[00051] In preferred aspects, the amphetamine process comprises wherein said providing a compound of Formula 4 comprises:
[00052] providing a compound of Formula 3:
NH2
, . . OH
H3C
[00053] 3 ; and
[00054] reacting the compound of Formula 3 with the appropriate
O
I I
/P-Cl
RO OR
[00055]
[00056] wherein R= alkyl or aryl
[00057] under conditions effective to produce a compound of Formula 4.
[00058] In preferred aspects, the amphetamine process involving Formula 4 comprises wherein the R= methyl, ethyl, isopropyl or phenyl.
[00059] In another preferred embodiment, the invention provides a compound of formula 6:
Figure imgf000008_0001
[00060]
[00061] prepared according to one or more processes herein, in a regioisomeric purity of > 1700:1
[00062] wherein:
[00063] R is alkyl or aryl
[00064] In preferred aspects, the invention further comprises a compound of formula 6:
Figure imgf000008_0002
[00065]
[00066] wherein the alkyl group is selected from the group consisting of methyl, ethyl or isopropyl.
[00067] In preferred aspects, the invention further comprises a compound of formula 6:
Figure imgf000008_0003
[00068]
[00069] wherein the aryl group is phenyl.
[00070] In another preferred embodiment, the invention provides a compound of formula 2:
P(0)(OR)2
N
H3C
2
[00071]
[00072] wherein: R is alkyl or aryl
[00073] In preferred aspects, the invention further comprises a compound of formula 2:
P(0)(OR)2
N
[00074] [00075] wherein the alkyl group is selected from the group consisting of methyl, ethyl or isopropyl.
[00076] In preferred aspects, the invention further comprises a compound of formula 2:
P(0)(OR)2
N
H3C
[00077] 2
[00078] wherein the aryl group is phenyl.
[00079] In yet another preferred embodiment, there is provided a process for the synthesis of amphetamine derivatives comprising the step of performing an organo cuprate addition reaction upon an aziridine phosphoramidate compound to obtain an aryl or aryl-alkyl
phosphoramidate amphetamine precursor.
[00080] In yet another preferred embodiment, there is provided a process for crystallization of compounds 6a-d from a mixture of compounds 6a-d and 8a-d, comprising the step of performing a crystallization using a mixture of two or more solvents wherein at least one of the two or more solvents is THF.
DETAILED DESCRIPTION OF THE INVENTION
[00081] Accordingly, the present invention relates to processes for the synthesis of amphetamine, dexamphetamine, methamphetamine, derivatives of these, including their salts, and novel precursors and intermediates obtained thereby, by synthesizing aziridine phosphoramidate compounds in specified solvents at specified temperatures, and then converting to a novel aryl or aryl-alkyl phosphoramidate precursor using an organometallic compound such as a copper salt, where the novel aryl or aryl-alkyl phosphoramidate precursor is then easily converted to the target compounds using known reactions, e.g. acid dephosphorylation, alkylation of the nitrogen followed by acid dephosphorylation, etc.
[00082] Alkyl means any C1-C10 straight or branched chain alkyl, wherein said alkyl, is optionally substituted with CI -C6 alkyl, C2 -C6 alkenyl, hydroxy, amino, halo, haloalkyl, thiocarbonyl, ester, thioester, alkoxy, alkenoxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, or sulfonyl. [00083] Aryl means any alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is either unsubstituted or substituted with one or more substituent(s) independently selected from the group including, but not limited to, alkylamino, amido, amino, aminoalkyl, azo, benzyloxy, CI -C9 straight or branched chain alkyl, CI -C9 alkoxy, C2 -C9 alkenyloxy, C2 -C9 straight or branched chain alkenyl, C3-C8 cycloalkyl, C5-C7 cycloalkenyl, carbonyl, carboxy, cyano, diazo, ester, formanilido, halo, haloalkyl, hydroxy, imino, isocyano, isonitrilo, nitrilo, nitro, nitroso, phenoxy, sulfhydryl, sulfonylsulfoxy, thio, thioalkyl, thiocarbonyl, thiocyano, thioester, thioformamido, trifluoromethyl, and carboxylic and heterocyclic moieties, including alicyclic and aromatic structures; wherein the individual ring size is 5-8 members;
wherein said heterocyclic ring contains 1-6 heteroatom(s) independently selected from the group consisting of 0, N, and S; and wherein said aromatic or tertiary alkyl amine is optionally oxidized. Useful carbo- and heterocyclic rings include without limitation phenyl, benzyl, naphthyl, indenyl, azulenyl, fluorenyl, anthracenyl, indolyl, isoindolyl, indolinyl, benzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benzthiazolyl, tetrahydrofuranyl, tetrahydropyranyl, pyridyl, pyrrolyl, pyrrolidinyl, pyridinyl, pyrimidinyl, purinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, quinolizinyl, furyl, thiophenyl, imidazolyl, oxazolyl, benzoxazolyl, thiazolyl, isoxazolyl, isotriazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, trithianyl, indolizinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, thienyl, tetrahydroisoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, and phenoxazinyl.
[00084] R may also be in certain preferred embodiments any C2-C10 straight or branched chain alkenyl or C1-C10 alkoxy, unsubstituted or optionally substituted with moieties listed above.
[00085] Copper includes CuCl, CuCl2, CuBr, CuF, Cul, Cu(OAc)2, Cu(OMe)2, Copper
nanoparticles, Copper turnings, or combinations thereof. Copper nanoparticles means particles having an average diameter of about lnm -lOOnm.
[00086] Alkyl Phosphonic Acid Protecting group means any group attached to the aziridine nitrogen having one or more alkyl groups attached to a phosphorous atom thereby having the formula P-0-(OR)2, where Rl and R2 can be the same or different, and include without limitation any alkyl, alkoxy or aryl group as defined herein, and including any and all equivalents thereof.
[00087] Solvents, as used and exemplified herein, are not intended to be limiting and may include without limitation solvents selected from Ligroine, Pentane, Hexane, Heptane, Octane, Cyclopentane, Cyclohexane, Cycloheptane, Cyclooctane, Dichloromethane, Chloroform, Carbon tetrachloride, 1,2-Dichloroethane, 1,1,2,2-Tetrachloroethane, Methylacetate, Ethylacetate, Propylacetate, Butylacetate, Dimethylformamide, Diethylformamide, Dimethylacetamide,
20
Diethylacetamide, Diethylether, Diisopropylether, methyl tert-Butyl ether, THF, Dioxane, Acetonitrile, Sulfolane, DMSO, HMPT, NMP or mixtures of these solvents. Preferred solvents are Dichloromethane, Chloroform, Ethyl acetate, Propyl acetate, Butyl acetate, Dimethylformamide, Diethylformamide, Dimethylacetamide, Diethylacetamide, Diisopropylether, methyl tert-Butyl ether, THF, Dioxane, Acetonitrile or mixtures of these. Especially preferred solvents are
Dichloromethane, Chloroform, Ethyl acetate, Butyl acetate, Dimethylformamide,
Dimethylacetamide, methyl tert-Butyl ether, THF, Dioxane, Acetonitrile or mixtures of these.
[00088] The term, regioselective or regioselectivity, means without limitation, by way of explanation, the preference of one direction of chemical bond making or breaking over all other possible directions. It can often apply to which of many possible positions a reagent will affect, such as which proton a strong base will abstract from an organic molecule, or where on a substituted benzene ring a further substituent will add. Because of the preference for the formation of one product over another, the reaction is selective. This reaction is regioselective because it selectively generates one constitutional isomer rather than the other. When a reaction is regioselective to the point that no other regioisomers are observed, the reaction is defined as being regiospecific.
[00089] The term, stereoselective or stereoselectivity, means without limitation, by way of explanation, the property of a chemical reaction in which a single reactant forms an unequal mixture of stereoisomers during the non-stereospecific creation of a new stereocenter or during the non-stereospecific transformation of a pre-existing one. The selectivity arises from differences in steric effects and electronic effects in the mechanistic pathways leading to the different products.
[00090] Zwierzak et al. teach in Tetrahedron 1997, 53, 4935-4946 that the product from the organocuprate addition to the 2-alkyl-N-(diethylphosphoryl)aziridines is always regiospecific, always occurring with nucleophilic attack at the less substituted carbon atom of the aziridine ring. Zwierzak continues the paragraph by explaining that diethyl N-sec-alkylphosphoramidate products could be easily isolated in pure state after quenching the organocuprate reaction mixture with aqueous ammonium chloride solution and no further purification is necessary before deprotection. It was discovered in attempting to implement the Zwierzak procedure, that this is not the case. In fact, irrespective of the esters on the phosphoramidate, the crude product (6a,b,c or d) is not of acceptable purity to proceed with. Further, it has also been discovered that, where the process generates 3-5% of 8 (a,b,c or d respectively) in the crude product, that it could not be readily removed after the deprotection or later in the synthetic sequence. It was also found that if you used a single solvent recrystallization of 6a, then you did not remove the corresponding 8a. As example, 6a readily crystallizes from hexane, heptane, isooctane or petroleum ether, but the residual 8a is still present It is required to leave a residue of the reaction solvent (THF) in the solvent mixture to separate the 6a from 8a. Interestingly, it has been discovered that a ratio of specific solvents yielded the most preferred embodiment. This ratio comprises about 7 part heptane and 1 part THF for 6a. The other versions of 6 (b,c or d) needed other recrystallization solvent mixtures, but the common item was that it was required to leave a residue of THF in the mixture.
[00091] Experimental Introduction :
[00092] Unless otherwise noted, reagents and solvents were used as received from commercial suppliers.
[00093] NMR spectra: Proton nuclear magnetic resonance spectra were obtained on a Bruker
AV 300 or a Bruker AV 500 spectrometer at 300 MHz and 500 MHz, respectively. Spectra are given in ppm (δ) and coupling constants, J, are reported in Hertz. Tetramethylsilane was used as an internal standard for proton spectra.
[00094] HPLC analyses: Analyses were obtained on a Varian Prostar 210 HPLC system using a
Prevail C18 column (53 x 7 mm, Alltech) with PDA detection at 208-210 nm and solvent gradient program Method A.
[00095] Method A:
Figure imgf000012_0001
0.0 2.0 95.0 5.0
10.0 2.0 5.0 95.0
11.5 2.0 5.0 95.0
11.6 2.0 95.0 5.0
13.0 2.0 95.0 5.0
[00096] A = Water with 0.05% v/v Trifluoro acetic Acid
[00097] B = Acetonitrile with 0.05% v/v Trifluoro acetic Acid
[00098] Method B
[00099] Flow rate: 0.7 rnL/min
[000100] Run time : 35 min
[000101] Temp: ambient
[000102] Mobile phase: 90% water pH = 1.5 (perchloric acid): 10% Methanol
[000103] GC (FID): Analyses were obtained on a Varian CP 3800 GC using a Supleco (Cat #
24048) SPB-5 30 x 0.320; 0.25 μιη column.
[000104] Column temperature initial: 50 °C
[000105] Column temperature final: 275 °C
[000106] Ramp profile: 20.0 deg/min
[000107] Injector temperature: 250 °C
[000108] Detector temperature: 250 °C
[000109] Carrier Gas/ flow rate: Helium, 2 mL/min
[000110] Example 1: Preparation of diethyl (2methylaziridin-l-yl)phosphonate (2a):
[000111]
Figure imgf000013_0001
[000112] A 12 L 4-neck flask fitted with an overhead mechanical stirrer, temperature probe and 1 L pressure equalizing addition funnel was charged with 2-methylaziridine (300 g, 5,25 mol purchased from Menadiona SL of Barcelona, Spain), triethylamine (880 mL, 6.3 mol) and dichloromethane (3.0 L). The stirred solution was cooled to 5 °C and diethoxyphosphoryl chloride (804 mL, 5.51 mol) was added over 2.5 hours while maintain the internal temperature below 15 °C. The reaction was then stirred for 18 hours, at which point the reaction was complete reaction was complete by TLC analysis (silica gel plate, 93:6: 1 dichloromethane/MeOH/NH4OH and 6/3/1 CHCl3/MeOH/NH4OH; KMn04 stain). Water (3 L) was charged and the biphasic mixture was stirred for 20 minutes. The layers were separated and the organic layer was concentrated under reduced pressure. The remaining yellow oil was clarified by filtration. The filtrate (1028 g) was purified by short path vacuum distillation at 66-67 °C, 1.0 mm Hg. to afford 2a as a colorless liquid (864.8 g, 85% yield, 99.0% GC purity). Ή NMR (300 MHz, CDC13) δ 4.15 (dq, J= 8.0, 7.1 Hz, 4H), 2.64 - 2.45 (m, 1H), 2.33 (ddd, J= 17.9, 5.9, 1.3 Hz, 1H), 1.91 - 1.81 (m, 1H), 1.34 (dt, J= 7.1, 0.9 Hz, 6H), 1.28 (dd, J= 5.4, 1.4 Hz, 3H).
Example 2: Preparation of diphenyl (2methylaziridin-l-yl)phosphonate (2b):
Figure imgf000014_0001
[000115] Compound 2b is prepared as described in Stephens, Moffett, Vaughan, Hill and Brown in the Journal of Chemical and Engineering Data, 1969, 14, 114-116, but substituting toluene for benzene, and is obtained as a thick colorless oil in about 55% yield after vacuum distillation. Expected JH NMR (300 MHz, CDC13) 5 7.40- 7.15 (m, 10H), 2.81 - 2.69 (m, 1H), 2.62 - 2.49 (dd, J= 17.6, 5.6 Hz, 1H), 2.10 - 2.00 (dd, J= 14.1, 4.9 Hz, 1H) and 1.28 - 1.24 ppm (m, 3H).
[000116] Example 3: Preparation of dimethyl (2methylaziridin-l-yl)phosphonate (2c):
[000117]
1.05 eq ClP(0)(OMe)2 D/nwnil .
H 1.20 eq Et3N P(0)(OMe)2
N N
1 CH2C12 . 2c
[000118] Compound 2c is prepared following the general procedure in Stephens, Moffett,
Vaughan, Hill and Brown in the Journal of Chemical and Engineering Data, 1969, 14, 114-116 but substituting toluene for benzene, and is obtained as a colorless oil in about 73% yield after vacuum distillation (75-80 °C @ 10 mm Hg vacuum). Expected *H NMR (300 MHz, CDC13) δ 3.80 (s, 3H), 3.76 (s, 3H), 2.65-2.50 (m, 1H), 2.42-2.31 (dd, J= 17.6, 5.6 Hz, 1H), 1.92 - 1.85 (dd, J= 14.1, 4.9 Hz, 1H), 1.28 (dd,/ = 5.4, 1.2 Hz, 3H).
[000119] Example 4: Preparation of diisopropyl (2methylaziridin-l-yl)phosphonate (2d):
[000120]
)(OiPr)2
Figure imgf000015_0001
[000121] Compound 2d is prepared following the general procedure in Stephens, Moffett,
Vaughan, Hill and Brown in the Journal of Chemical and Engineering Data, 1969, 14, 114-116 but substituting toluene for benzene, and is obtained as a colorless oil in about 80% yield after vacuum distillation (79 - 82 °C @ 3 mm Hg vacuum). Expected !H NMR (300 MHz, CDC13) δ 4.71 (m, 2H), 2.64 - 2.41 (m, 1H), 2.28 (dd, J= 17.6, 5.6 Hz, 1H), 1.81 (dd, J= 14.1, 4.9 Hz, 1H), 1.34 (m, 12H) and 1.22 (dd, J= 5.6, 1.2 Hz, 3H).
Example 5: Preparation of diethyl (2methylaziridin-l-yl)phosphonate (2a), alternate
NH,
Figure imgf000015_0002
in. 4.0 eq KOH
(3 M) P(0)(OEt)2
>~ N
5-10 °C 2 h
then
2a
40 °C 6 h
[000124] A 2 L 3 -neck flask fitted with an overhead mechanical stirrer and 50 mL pressure equalizing addition funnel was charged with 2-aminopropanol (25.0 g, 332 mmol), triethylamine (57.8 mL, 416 mmol, 1.25 equivalents) and tetrahydrofuran (800 mL). The stirred solution was cooled to +4 °C and diethoxyphosphoryl chloride (57.9 mL, 399 mmol, 1.20 equivalents) was added over 20 minutes while maintaining an internal temperature <+15°C. The reaction mixture was stirred an additional 30 minutes at which point the reaction was complete by TLC analysis (silica gel plate, 93 :6: 1
dichloromethane/MeOH/NH4OH and 6/3/1 CHCl3/MeOH/NH4OH; KMn04 stain). Additional triethylamine (57.8 mL, 416 mmol, 1.10 equivalents) was added to the reaction mixture and
methanesulfonyl chloride (32.3 mL, 416 mmol, 1.25 equivalents) was added drop-wise over 25 minutes while maintaining an internal temperature <+18 °C. The resulting reaction mixture was stirred for 1.5 hours at which time TLC analysis (see above methods) indicated the reaction was complete. Potassium hydroxide solution (3 M solution, 555 mL, 1.6 mo 1, 5.0 equivalents) was slowly added to the stirred reaction mixture while maintaining an internal temperature < +20°C. The reaction was stirred for 30 minutes and diluted with ethyl acetate (300 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (300 mL). The combined organic extract was washed with saturated sodium chloride solution (300 mL) and dried over anhydrous sodium sulfate. The solution was clarified and then concentrated under reduced pressure to afford crude 2 as an orange oil. The oil was purified by short path distillation (72-74 °C, 10 mm Hg vacuum) to afford purified 2a as a colorless oil (48.2 g,
75% yield, 99.0 % GC purity). Ή NMR (300 MHz, CDC13) δ 4.15 (dq, J = 8.0, 7.1 Hz, 4H), 2.64 - 2.45 (m, 1H), 2.33 (ddd, J = 17.9, 5.9, 1.3 Hz, 1H), 1.91 - 1.81 (m, 1H), 1.34 (dt, J= 7.1, 0.9 Hz, 6H), 1.28 (dd, J= 5.4, 1.4 Hz, 3H).
[000125] Example 6: Preparation of diphenyl (2methylaziridin-l-yl)phosphonate (2b) alternate route:
Figure imgf000016_0001
Hi. 4.0 eq KOH
(3 M) P(0)(OPh)2
Figure imgf000016_0002
[000127] Following the procedure for the alternate preparation of 2a, diphenyl (2methylaziridin-l- yl)phosphonate (2b) is prepared as a thick colorless oil in about 30% yield (expected minimum 97% GC purity). Expected Ή NMR (300 MHz, CDC13) δ 7.40- 7.15 (m, 10H), 2.81 - 2.69 (m, 1H), 2.62 - 2.49 (dd, J= 17.6, 5.6 Hz, 1H), 2.10 - 2.00 (dd, J= 14.1, 4.9 Hz, 1H) and 1.28 - 1.24 ppm (m, 3H).
[000128] Example 7: Preparation of dimethyl (2methylaziridin-l-yl)phosphonate (2c) alternate route:
Figure imgf000017_0001
Hi. 4.0 eq KOH
(3 M) P(0)(OMe)2
*► N
5-10 °C 2 h J-^
then
40 °C 6 h 2c
[000130] Following the procedure for the alternate preparation of 2a, dimethyl (2methylaziridin-l- yl)phosphonate (2c) is prepared as a viscous colorless oil in about 70% yield (expected 95% GC minimum purity). Expected Ή NMR (300 MHz, CDCI3) δ 3.80 (s, 3H), 3.76 (s, 3H), 2.65-2.50 (m, 1H), 2.42-2.31 (dd, J= 17.6, 5.6 Hz, 1H), 1.92 - 1.85 (dd, J = 14.1, 4.9 Hz, 1H), 1.28 (dd,/ = 5.4, 1.2 Hz, 3H).
[000131] Example 8: Preparation of diisopropyl (2methylaziridin-l-yl)phosphonate (2d) alternate route:
[000132] NH, 1
OH
Figure imgf000018_0001
Hi. 4.0 eq KOH
(3 M) P(0)(OMe)2
N
5-10 °C 2 h
then
40 °C 6 h 2d
[000133] Following the procedure for the alternate preparation of 2a, diisopropyl (2methylaziridin- l-yl)phosphonate (2d) is prepared as a viscous colorless oil in about 50 % yield (expected 95% GC minimum purity). Expected Ή NMR (300 MHz, CDC13) δ 4.71 (m, 2H), 2.64 - 2.41 (m, 1H), 2.28 (ddd, J = 17.6, 5.6, 1.3 Hz, 1H), 1.81 (dd, J = 14.1, 4.9, 1.3 Hz, 1H), 1.34 (m, 12H) and 1.22 (dd, J = 5.6, 1.2 Hz, 3H).
[000134] Example 9: Preparation of diethyl (l-phenylpropan-2-yl)phosphoramidate (6a) [Cul catalyst):
[000135]
GC ratio = 97:3
Figure imgf000018_0002
6a purified
[000136] A 250 mL, jacketed, three necked flask equipped with an overhead stirrer, 50 mL pressure equalizing addition funnel and a temperature probe was charged with 2a (10 g, 51.7 mmol), THF (50 mL) and Cul (98 mg, 1.0 mol%) and the stirred mixture was heated to 30 °C. The pressure equalizing addition funnel was charged with PhMgCl (2M in THF, 32.36 mL) and the solution was added over 20 minutes while maintaining an internal temperature of 30 - 32 °C. After the addition was complete, the reaction mixture was heated to 45-50 °C for an additional 30 minutes and then cooled to ambient temperature. The reaction was quenched by slow addition to a cooled mixture of saturated aqueous ammonium chloride solution and water (50/50 v/v, 100 mL) while maintaining an internal temperature below 20 °C. The flask was rinsed with methyl t- butyl ether (100 mL) and the rinse was transferred to the quenched reaction mixture. The biphasic mixture was stirred for 5 minutes, allowed to separate for 20 minutes and then the aqueous phase was removed. The organic phase washed with saturated sodium chloride solution (50 mL) and the organic phase was dried over sodium sulfate. The solution (a 97:7 mixture of 6a: 8a by GC analysis) was filtered and concentrated under reduced pressure until the product began to crystallize. Heptane (40 mL) was added to the slurry and the mixture was heated until a solution was obtained. The stirred solution allowed to cool to room temperature and stirred for 18 hours. The solid was collected by filtration and dried under reduced pressure at 30°C for 18 hours affording diethyl (l-phenylpropan-2-yl)phosphoramidate (6a) as a white crystalline solid (9.12 g, 65% yield; 99.72% GC purity with 0.04% 8a present). Mp 66-67°C (lit1 57-58 °C). *H NMR (300 MHz, CDCls) δ 7.36 - 7.08 (m, 5H), 4.14 - 3.85 (m, 3H), 3.85 - 3.66 (m, 1H), 3.58 - 3.32 (m, 1H), 2.81 - 2.61 (m, 2H), 2.38 (t,/ = 9.8 Hz, 1H), 1.38 - 1.18 (m, 6H), 1.15 (d,/ = 6.4 Hz, 3H).
[000137] Example 10: Preparation of diethyl (l-phenylpropan-2-yl)phosphoramidate (6a) [CuCl catalyst]:
[000138]
GC ratio = 97:3
Figure imgf000020_0001
6a purified
[000139] A 12 L, jacketed, bottom outlet flask was charged with 2a (700 g, 3.62 mol), THF (3.5 L) and CuCl (3.58 g, 1.0 mol%) and the stirred mixture was heated to 45 °C. A pressure equalizing addition funnel was charged with PhMgCl (2M in THF, 2.26 L) and the solution was added slowly while maintaining an internal temperature below 52°C. After the addition was complete, the reaction mixture was stirred at 48-51 °C for an additional 30 minutes. GC analysis indicated the consumption of 2a (< 1.0%) and the reaction mixture was cooled to ambient temperature. The reaction was quenched by slow addition to a cooled mixture of saturated aqueous ammonium chloride solution and water (50/50 v/v, 4.2 L) while maintaining an internal temperature below 25 °C. The flask was rinsed with heptanes (3.5 L) and the rinse was transferred to the quenched reaction mixture. The biphasic mixture was stirred for 5 minutes, allowed to separate for 20 minutes and then the aqueous phase was removed. The organic phase was concentrated under reduced pressure to a volume of about 1.0 L. The organic solution was azeotropically dried by two separate charges of heptanes (2 X 2.0L) was added and the solution volume was adjusted by reduced pressure distillation to a total volume of about 2.5 L. The slurry was heated to 60-65 °C until the solids dissolved and then stirrer was slowed and the crystallization was allowed to proceed for about 24 hours as the batch cooled to ambient temperature. The slurry was cooled to 5 °C for about 1.5 hours. The resulting crystalline solid was collected by vacuum filtration and washed with cold heptanes (2 x 350 mL). After drying under vacuum at 35 °C for 48 hours the diethyl (l-phenylpropan-2-yl)phosphoramidate (6a) was obtained as a white crystalline solid
(806.1 g, 82% yield; 99.90% GC purity with 0.04% 8a present). Mp 64-65°C (lit1 57-58 °C). *H NMR (300 MHz, CDC13) δ 7.36 - 7.08 (m, 5H), 4.14 - 3.85 (m, 3H), 3.85 - 3.66 (m, 1H), 3.58 - 3.32 (m, 1H), 2.81 - 2.61 (m, 2H), 2.38 (t,/ = 9.8 Hz, 1H), 1.38 - 1.18 (m, 6H), 1.15 (d,/ = 6.4 Hz, 3H). [000140] The phenyl Grignard can be either be purchased commercial solutions, at about 2 moles of active reagent per liter of solution, or prepared in situ from the corresponding
halobenzene and magnesium metal turnings. For phenylmagnesium chloride, the solvents of choice are either THF or 2-methylTHF. For phenylmagnesium bromide, the solvents of choice are either THF, 2-methylTHF or diethyl ether. For phenylmagnesium iodide the solvent of choice is diethyl ether. The use of any of these ether solvents (alone or mixed with toluene) in conversion to 2a to 6a, following the established procedure, affords 6a in comparable isolated yield, GC purity and devoid of the regioisomer 8a.
[000141] The use of other copper sources (CuCl2, CuBr, CuF, Cu(OAc)2, Cu(acac)2, Cu(OMe)2, Copper nanoparticles and Copper turnings) in conversion to 2a to 6a, following the established procedure, affords 6a in comparable isolated yield, GC purity and devoid of the regioisomer 8a.
Example 11: Preparation of diphenyl (l-phenylpropan-2-yl)phosphoramidate
GC ratio = 95:5
Figure imgf000021_0001
6b purified
[000144] A 100 mL, 3-necked flask equipped with an overhead stirrer, reflux condenser and pressure equalizing addition funnel was charged with 2b (10.0 g, 34.6 mmol), THF (50 mL) and CuCl (42 mg, 1 mol%) and the stirrer was started. The stirred mixture was heated to 48 °C and the pressure equalizing addition funnel was charged with PhMgCl (2M in THF, 17.4 mL). This solution was added slowly while maintaining a reaction temperature of 48-51 °C. The reaction was allowed to stir at 48-51 °C for an additional 2 hours until the GC analysis indicated the
consumption of 2b (< 1.0%) and the reaction mixture was cooled to ambient temperature. The reaction was quenched by slow addition to a cooled solution of saturated aqueous ammonium chloride/water mixture (50/50 v/v, 60 mL) while maintaining the batch temperature below 20 °C. Heptanes (60 mL) was used to rinse the reactor and was transferred to the quench mixture. The biphasic mixture was agitated for 15 minutes and the aqueous layer was removed. The organic layer washed with deionized water (20 mL) and the organic phase concentrated under reduced pressure to give viscous oil. This residue was dissolved in heptanes (50 mL) and the solution was concentrated under reduced pressure. The residue was crystallized from ethanol (1 g/5 mL) to give 6b as a white solid (9.05 g, 72% yield, 99.85% GC purity containing 0.05% of 8b). Mp 102- 103 °C (lit1 101-102 °C). H NMR (300 MHz, CDC13) δ 7.38 - 7.11 (m, 15H), 3.83 - 3.65 (m, 1H), 3.00-2.89 (m, 1H), 2.86-2.78 (m, 1H), 2.73-2.62 (m, 1H), 1.15 (d,/ = 10.1 Hz, 3H).
Example 12: Preparation of dimethyl (l-phenylpropan-2-yl)phosphoramidate
GC ratio = 97.5:2.5
Figure imgf000022_0001
H3C
6c purifled
[000147] A 100 mL, 3-necked flask equipped with an overhead stirrer, reflux condenser and pressure equalizing addition funnel was charged with 2c (10.0 g, 60.5 mmol), THF (60 mL) and CuCl (70 mg, 1 mol%) and the stirrer was started. The mixture was heated to 48 °C and the pressure equalizing addition funnel was charged with PhMgCl (2M in THF, 13 mL). This solution was added slowly while maintaining an internal temperature of 48-51 °C. The reaction was stirred at 48-51 °C for an additional 30 minutes until the GC analysis indicated the consumption of 2c (< 1.0%) and the reaction mixture was cooled to ambient temperature. The reaction was quenched by slow addition to a cooled solution of saturated aqueous ammonium chloride in water (50/50 v/v, 100 mL) while maintaining the temperature below 20 °C. Heptanes (100 mL) was used to rinse the reactor and the rinse solution was transferred to the quenched reaction mixture. The mixture was agitated for 15 minutes, allowed to separate for 30 minutes then the aqueous phase was discarded. The organic phase washed with deionized water (30 mL) and the organic phase concentrated under reduced pressure to give an oil. The residue was dissolved in heptanes (100 mL) and the solution was concentrated under reduced pressure. The residue was
crystallized from methyl tert-butyl ether (lg/3mL), filtered and dried to give 6c as white needles (10.2 g; 74.8 % yield), with 99.90% GC purity containing 0.06% 8c. Mp 86-88 °C. *H NMR (300 MHz, CDCls) δ 7.32 - 7.17 (m, 5H), 3.66 (d,/ = 6.4 Hz, 3H), 3.50-3.83 (m, 1H), 2.71 (d,/ = 6.6 Hz, 2H), 2.45 (m, 1H), 1.15 (d,/ = 6.6 Hz, 3H).
[000148] Example 13: Preparation of diisopropyl (l-phenylpropan-2- yljphosphoramidate (6d):
[000149]
Figure imgf000023_0001
6d purified
[000150] Following the procedure for the alternate preparation of 6a, diisopropyl (1- phenylpropan-2-yl)phosphoramidate (6d) is prepared as a viscous colorless oil in about 50 % yield (expected GC purity: > 99.7% 6d with < 0.1% 8d). Expected *H NMR (300 MHz, CDC13) δ 7.32 - 7.17 (m, 5H), 4.59 - 4.41 (m, 2H), 3.53 - 3.41 (m, 1H), 2.86 - 2.80 (m, 1H), 2.69 - 2.61 (m, 1H), 2.36 (t,/ = 9.6 Hz, 1H), 1.32 - 1.26 (m, 12H), 1.08 (d,/ = 10.1 Hz, 3H). [000151] Example 14: Preparation of amphetamine (7) from 6a:
[000152]
Figure imgf000024_0001
v. distillation
[000153] A 12 L, jacketed, bottom outlet valve flask was charged with 6a (800 g, 2.95 mol) and 3 M hydrochloric acid (3.0 L) and the reaction mixture was heated to 80 °C for 1.5 hours at which point HPLC analysis indicated that the reaction was complete, and then cooled to room temperature. The brown solution was washed with ethyl acetate (1.5 L) and the organic extract layer was discarded. Sodium hydroxide solution (50% solution, 560 mL) was slowly added to the remaining aqueous layer, keeping the temperature below 25 °C. Methyl tert-butyl ether (1.0 L) was added and the mixture was agitated for 20 minutes then allowed to separate for 30 minutes. The aqueous layer was removed and the organic layer was concentrated under reduced pressure to afford a light yellow oil. This oil was short path distilled (75-78°C at 10 mmHg vacuum) to give racemic amphetamine (7) as a clear colorless oil (335.76 g, 84.3% yield; 99.93% pure by GC). Ή
NMR (300 MHz, CDC13) δ 7.36 - 7.26 (m, 2H), 7.23 - 7.13 (m, 3H), 3.26 - 3.03 (m, 1H), 2.72 (dd,/ = 13.2, 5.4 Hz, 1H), 2.53 (dd,/ = 13.2, 8.0 Hz, 1H), 1.20 (br s, 2H), 1.13 (d, / = 6.3 Hz, 3H).
[000154] Example 15: Preparation of amphetamine (7) from 6b:
[000155]
Figure imgf000024_0002
v. distillation
[000156] A 50 mL flask is charged with 6b (7.5 g, 20.41 mmol) and 3 M HCl (20.0 mL) and the stirred reaction mixture is heated to 80 °C for 32 hours, at which point HPLC analysis should indicate the reaction is complete, and it is cooled to room temperature. The organic layer is washed with ethyl acetate (2 x 25 mL) and the organic extracts are discarded. The aqueous layer is treated with sodium hydroxide solution (50%, 12.0 mL) keeping the temperature below 25 °C. Methyl tert-butyl ether (50 mL) is added and the reaction mixture is agitated for 5 minutes and then separated. A second portion of methyl tert-butyl ether (50 mL) is added and the reaction mixture is agitated for 5 minutes. The combined organic extracts are washed with water (10 mL) and the organic layer is concentrated under reduced pressure to give 7 as a colorless oil in about 80% yield. The expected purity is > 99% by GC purity and 99% by HPLC. The expected Ή NMR spectra (300 MHz, CDC13) is δ 7.36 - 7.26 (m, 2H), 7.23 - 7.13 (m, 3H), 3.26 - 3.03 (m, 1H), 2.72 (dd,/ = 13.2, 5.4 Hz, 1H), 2.53 (dd,/ = 13.2, 8.0 Hz, 1H), 1.20 (br s, 2H), 1.13 (d,/ = 6.3 Hz, 3H) and matches the reference spectra.
[000157] Example 16: Preparation of amphetamine (7) from 6c:
[000158]
Figure imgf000025_0001
v. distillation
[000159] A 50 mL flask is charged with 6c (5.0 g, 20.6 mmol) and 3 M HCl (20.0 mL) and the stirred reaction mixture is heated to 80 °C for 1 hour, at which point HPLC analysis indicates the reaction is complete, and it is cooled to room temperature. The reaction mixture is washed with ethyl acetate (2 x 20 mL) and the organic extracts are disposed. The aqueous layer is treated with sodium hydroxide solution (50%, 12.0 mL) keeping the internal temperature below 25 °C. Methyl tert-butyl ether (15 mL) is added and the reaction mixture is agitated for 15 minutes then allowed to separate. The organic layer is washed with water (10 mL) and organic layer is concentrated under reduced pressure to give 7 as a colorless oil in about 88.0% yield. The expected purity is
>99.5 % by GC and >99% by HPLC. The expected *H NMR spectra (300 MHz, CDC13) is δ 7.36 - 7.26 (m, 2H), 7.23 - 7.13 (m, 3H), 3.26 - 3.03 (m, 1H), 2.72 (dd,/ = 13.2, 5.4 Hz, 1H), 2.53 (dd,/ = 13.2, 8.0 Hz, 1H), 1.20 (br s, 2H), 1.13 (d,/ = 6.3 Hz, 3H) and matches the reference spectra.
[000160] Example 17: Preparation of amphetamine (7) from 6d: [000161]
Figure imgf000026_0001
¾C
iv. M BE extraction
6(1
v. distillation
[000162] Following the procedure for the preparation of amphetamine (7) from 6a,
amphetamine (7) is prepared from diisopropyl (l-phenylpropan-2-yl)phosphoramidate (6d) as a colorless oil. The expected *H NMR spectra (300 MHz, CDC13) is δ 7.36 - 7.26 (m, 2H), 7.23 - 7.13 (m, 3H), 3.26 - 3.03 (m, 1H), 2.72 (dd,/ = 13.2, 5.4 Hz, 1H), 2.53 (dd,/ = 13.2, 8.0 Hz, 1H), 1.20 (br s, 2H), 1.13 (d,/ = 6.3 Hz, 3H) and matches the reference spectra.
Example 18: Preparation of Impurities 8a-d:
Figure imgf000026_0002
a R=Et 8a R=Et
b R=P 8b R=Ph
c R=Me 8c R=Me
d R=iPr 8d R=iPr
[000165] A 100 mL 3-neck flask was charged with commercial 8 (1.0 g, 7.4 mmol, from Aldrich Chemical), Et3N (1.23 mL, 8.8 mmol), and dichloromethane (25 mL). The solution was cooled to 0-5 °C and a solution of the appropriate chlorophosphate (8.15 mmol of a through d) in dichloromethane (5 mL) was added over 5 minutes. The reaction mixture was allowed to stir at ambient temperature overnight. The reaction mixture was then quenched by adding water (20 mL) and the organic layer was separated. The organic extract was washed with IN HC1 solution (10 mL), saturated NaHC03 solution (10 mL), and saturated sodium chloride solution (10 mL). The organic phase was concentrated to dryness to afford the desired product, 8a-d. [000166] 8a: 81% yield, colorless oil. 95.8% GC purity.1!! NMR (300 MHz, CDC13) δ 7.30-7.19 (m, 5H), 3.68 (d,/ = 11.1 Hz, 3H), 3.63 (d,/ = 11.1 Hz, 3H), 3.20-3.00 (m, 2 H), 2.95-2.80 (m, 1H), 2.45 (s, br, 1H), 1.26 (d,/ = 6.9 Hz, 3H).
[000167] 8b: 91% yield, colorless oil. 95.16% GC purity.iH NMR (300 MHz, CDCI3) δ 7.26- 7.04 (m, 15H), 3.48 (s, br, 1H), 3.35-3.22 (m, 1 H), 3.03-2.90 (m, 2H), 1.21 (m, 3H).
[000168] 8c: 85% yield, colorless oil. 97.47% GC purity!H NMR (300 MHz, CDCI3) δ 7.32-7.19 (m, 5H), 4.04-3.91 (m, 4 H), 3.20-3.95 (m, 2 H), 2.92-2.80 (m, 1H), 2.45 (s, br, 1H), 1.26 (d,/ = 6.9 Hz, 3H).
[000169] 8d: The residue was chromatographed on a 40 g Combiflash Gold column eluting with 100% heptanes to 100% ethyl acetate over a 20-minute gradient. Combined clean fractions we concentrated to dryness to give the desired product as a clear colorless oil in 42% yield, 97.3% purity GC. *H NMR (300 MHz, CDCI3) δ 7.37 - 7.10 (m, 5H), 4.61 - 4.44 (m, 2H), 3.20-2.91 (m, 2H), 2.90-2.78 (m, 1H), 2.41-2.28 (m, 1H), 1.35-1.16 (m, 15H).
[000170] 1) Cates, L. A.; Lawrence, W. H.; McClain, R. J. Journal of Pharmaceutical Sciences, 1966, 55, 1400 - 1403.
[000171] The references recited herein are incorporated herein in their entirety, particularly as they relate to teaching the level of ordinary skill in this art and for any disclosure necessary for the commoner understanding of the subject matter of the claimed invention. It will be clear to a person of ordinary skill in the art that the above embodiments may be altered or that insubstantial changes may be made without departing from the scope of the invention. Accordingly, the scope of the invention is determined by the scope of the following claims and their equitable
Equivalents.

Claims

CLAIMS WHAT IS CLAIMED IS:
1. A process of making the amphetamine, said process comprising: providing a compound of Formula 6:
Figure imgf000028_0001
wherein R is alkyl or aryl; and
deprotecting the compound of Formula 6 under acidic conditions effective to produce
amphetamine of Formula 7:
Figure imgf000028_0002
7
2. The process according to claim 1 wherein the acidic conditions are aqueous hydrochloric, sulfuric or phosphoric acids.
3. The process according to claim 2 wherein the aqueous acid water content is in an amount of 50% to 90%
4. The process according to claim 1 wherein the R= methyl, ethyl, isopropyl or phenyl.
5. The process according to claim 1, wherein said providing a compound of Formula 6 comprises: providing a compound of Formula 2:
P(0)(OR)2
N
H3C
2 wherein R is alkyl or aryl and
reacting the compound of Formula 2 with phenylmagnesium halide and a copper catalyst under solvent and temperature conditions effective to produce a compound of Formula 6 in a purity substantially free of any regioisomeric impurities.
6. The process according to claim 5 wherein the regioisomeric purity of Formula 6 is > 99% and the regioisomer (Formula 8) is < 0.1%.
7. The process according to claim 6 wherein the R= methyl, ethyl, isopropyl or phenyl.
8. The process according to claim 5 wherein the copper catalyst is CuCl, CuCl2, CuBr, CuF, Cul, Cu(OAc)2, Cu(acac)2, Cu(OMe)2, Copper nanoparticles, Copper turnings, or combinations thereof.
9. The process according to claim 5 wherein the solvent is an organic ether or an organic ether - toluene mixture.
10. The process according to claim 9 wherein the organic ether solvent is diethyl ether, tetrahydrofuran or 2-methyltetrahydrofuran.
11. The process according to claim 5 wherein the phenylmagnesium halide is either
phenylmagnesium chloride, phenylmagnesium bromide or phenylmagnesium iodide.
12 The process according to claim 11 wherein the phenylmagnesium halide solutions can either be commercially supplied or prepared in situ from the corresponding halobenzene and magnesium.
13. The process according to claim 12 wherein the magnesium can be in the form of chips, granules, ribbon, turnings, dust, grit, chunks, or combinations thereof.
14. The process according to claim 5 wherein said treating is carried out at a temperature of from about -10 °C to about 70 °C.
15. The process according to claim 11 wherein said treating is carried out at a temperature of from about 30 °C to about 60 °C.
16. The process according to claim 2, wherein said providing a compound of Formula 2 comprises:
providing a compound of Formula 5:
Figure imgf000030_0001
5
wherein R is alkyl or aryl; and
reacting the compound of Formula 5 with the base under conditions effective to produce a compound of Formula 2.
17. The process according to claim 16 wherein the R= methyl, ethyl, isopropyl or phenyl.
18. The process according to claim 16, wherein the base is potassium hydroxide or potassium carbonate.
19. The process according to claim 16, wherein said providing a compound of Formula 5 comprises:
providing a compound of Formula 4:
Figure imgf000031_0001
4
wherein R is alkyl or aryl; and
reacting the compound of Formula 4 with methanesulfonyl chloride and a base under conditions effective to produce a compound of Formula 5.
20. The process according to claim 19 wherein the R= methyl, ethyl, isopropyl or phenyl.
21. The process according to claim 19, wherein said providing a compound of Formula 4 comprises:
providing a compound of Formula 3:
NH2
, . . OH
H3C
3 and
reacting the compound of Formula 3 with the appropriate
O
I I
/P-Cl
RO VOR
wherein R= alkyl or aryl
under conditions effective to produce a compound of Formula 4
22. The process according to claim 21 wherein the R= methyl, ethyl, isopropyl or phenyl.
23. A compound of the formula 6:
Figure imgf000031_0002
6
prepared as per claim 5 in a regioisomeric purity of > 1700:1
wherein: R is alkyl or aryl.
24. A compound according to claim 23, wherein the alkyl group is selected from the group consisting of methyl, ethyl or isopropyl.
25. A compound according to claim 23 wherein the aryl group is phenyl.
26. A compound of the formula 2:
)(OR)2
Figure imgf000032_0001
2
wherein: R is alkyl or aryl.
27. A compound according to claim 26, wherein the alkyl group is selected from the group consisting of methyl, ethyl or isopropyl.
28. A compound according to claim 26 wherein the aryl group is phenyl.
29. A process for the synthesis of amphetamine derivatives comprising the step of performing a organo cuprate addition reaction upon an aziridine phosphoramidate compound to obtain an aryl or aryl-alkyl phosphoramidate amphetamine precursor.
30. A process for the crystallization of compounds 6a-d from a mixture of compounds 6a-d and 8a-d, comprising the step of performing a crystallization using a mixture of two or more solvents wherein at least one of the two or more solvents is THF.
PCT/US2015/017265 2014-02-25 2015-02-24 Synthesis of racemic amphetamine derivatives by cuprate addition reaction with aziridine phosphoramidate compounds WO2015130660A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14/189,630 2014-02-25
US14/189,630 US9278904B2 (en) 2013-12-31 2014-02-25 Synthesis of chiral amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds
US14/327,209 US9321794B2 (en) 2013-12-31 2014-07-09 Synthesis of racemic amphetamine derivatives by cuprate addition reaction with aziridine phosphoramidate compounds
US14/327,209 2014-07-09

Publications (1)

Publication Number Publication Date
WO2015130660A1 true WO2015130660A1 (en) 2015-09-03

Family

ID=54009542

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/017265 WO2015130660A1 (en) 2014-02-25 2015-02-24 Synthesis of racemic amphetamine derivatives by cuprate addition reaction with aziridine phosphoramidate compounds

Country Status (1)

Country Link
WO (1) WO2015130660A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9657041B2 (en) 2013-12-31 2017-05-23 Chemapotheca, Llc Chiral aryl or aryl-alkyl phosphoramidate dexamphetamine precursors having a regioisomeric purity >99%
WO2017098533A3 (en) * 2015-12-11 2017-08-10 Sun Pharmaceutical Industries Limited Process for preparation of lisdexamphetamine
US11717498B2 (en) 2013-12-31 2023-08-08 Pharmapotheca A, Inc. Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3584085A (en) * 1967-07-18 1971-06-08 Atlas Chem Ind Phosphoramidates

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3584085A (en) * 1967-07-18 1971-06-08 Atlas Chem Ind Phosphoramidates

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LI XINYAO ET AL.: "An Improved and Mild WenkerSynthesis of Aziridines", SYNTHESIS, vol. 20, 1 January 2010 (2010-01-01), pages 3423 - 3428 *
ZWIERZAK A . ET AL.: "Communications, ''Phosphoramidomercuration_Demercuration: A Simple, Two-Step Conversion of Alkenes into Alkamnines, November, 918-920, 1982.", SYNTHESIS, 1 January 1982 (1982-01-01), pages 918,920 *
ZWIERZAK A. ET AL.: "Synthesis of Primary sec-Alkylamines via Nucleophilic Ring-opening of N-Phosphorylated Aziridines", TETRAHEDRON, vol. 53, no. 13, 1997, pages 4935 - 4946, XP004771912, ISSN: 0040-4020 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9657041B2 (en) 2013-12-31 2017-05-23 Chemapotheca, Llc Chiral aryl or aryl-alkyl phosphoramidate dexamphetamine precursors having a regioisomeric purity >99%
US11717498B2 (en) 2013-12-31 2023-08-08 Pharmapotheca A, Inc. Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms
WO2017098533A3 (en) * 2015-12-11 2017-08-10 Sun Pharmaceutical Industries Limited Process for preparation of lisdexamphetamine

Similar Documents

Publication Publication Date Title
US10087202B2 (en) Chiral aziridine phosphoramidate compounds
ES2374379T3 (en) EXO AND DIASTEREOSELECTIVE SYNTHESIS OF HIMBACINE ANALOGS.
Nakamura et al. Organocatalytic enantioselective hydrophosphonylation of sulfonylimines having a heteroarenesulfonyl group as a novel stereocontroller
CN110683975B (en) Synthesis method of dialkyl amino alkyl dithioformate
KR20070056001A (en) Novel method for the preparation of intermediates useful for the synthesis of vitamin d analogues
AU2011322115A1 (en) Intermediate compounds and process for the preparation of Fingolimod
WO2015130660A1 (en) Synthesis of racemic amphetamine derivatives by cuprate addition reaction with aziridine phosphoramidate compounds
ES2836118T3 (en) Procedure for the Preparation of a Nitric Oxide Donor Prostaglandin Analog
CN107540574B (en) Preparation method of R-biphenylalaninol
Sobhani et al. One‐pot synthesis of primary 1‐aminophosphonates: Coupling reaction of carbonyl compounds, hexamethyldisilazane, and diethyl phosphite catalyzed by Al (OTf) 3
US9321794B2 (en) Synthesis of racemic amphetamine derivatives by cuprate addition reaction with aziridine phosphoramidate compounds
JP2022526893A (en) D-Metirosine Composition and Methods for Preparing It
EP3197875B1 (en) Processes for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
ES2446365T3 (en) Neramexane preparation procedure
US11873315B2 (en) Chiral n-heterocyclic phosphorodiamidic acids (NHPAS) and derivatives as novel Brønsted acid catalysts
EP1614672B1 (en) An amino alcohol ligand and its use in preparation of chiral proparglic tertiary alkohols and tertiary amines via enantioselective additon reaction
WO2019036349A1 (en) Directed b-c(sp3)-h iodination and arylation of ketones
JP2009215214A (en) METHOD FOR PRODUCING alpha-AMINOPHOSPHONIC ACID ESTER DERIVATIVE
EP0299484A1 (en) Process for the preparation of intermediates for the synthesis of fosfomycin
WO2020180825A1 (en) Application for letters patent
AU2021314375A1 (en) Method for large-scale synthesis of tetrodotoxin
Wone et al. Optimizing phenylethylphosphonamidates for the inhibition of prostate-specific membrane antigen
EP1812369A1 (en) A new process for the dimerisation of alkyl glyoxals
EP2673282B1 (en) Novel process for the preparation of dronic acids
US5233045A (en) Process for the preparation of imidazothiazolone derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15754775

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15754775

Country of ref document: EP

Kind code of ref document: A1